Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

Abstract: A CPR training manikin The training manikin can have a lighted rate monitor assembly. The lighted rate monitor can include a body portion, the body portion including an electronic control board. A chest compression assembly can be joined to the body portion, the chest compression assembly comprising input sensors electrically connected to the electronic control board. The lighted rate monitor assembly can have an electrical cord assembly having a plug member at a proximal end for removable electrical connection with the electronic control board, and having at a distal end, a light.

Abstract: Described herein are interleukin-10 receptor-2 peptides, antibodies that bind the peptides, compositions including the peptides and antibodies and methods of use of the peptides and antibodies. The interleukin-10 receptor-2 peptide consists of an 8-15 amino acid sequence that includes SEQ ID NO: 1 ((I/V)P(P/K/V/E)P(E/K/R/Q)N(A/V)R), SEQ ID NO: 2 ((S/L/V)PAF(A/P)(K/Q)(G/T/E)(N/T/D)), or SEQ ID NO: 3 (PP(G/T/Q/V)(V/T/A)(R/H/T/S)(GN/NHP/SAA)).

Abstract: Described herein are interleukin-10 receptor-2 peptides, antibodies that bind the peptides, compositions including the peptides and antibodies and methods of use of the peptides and antibodies. The interleukin-10 receptor-2 peptide consists of an 8-15 amino acid sequence that includes SEQ ID NO: 1 ((I/V)P(P/K/V/E)P(E/K/R/Q)N(A/V)R), SEQ ID NO: 2 ((S/L/V)PAF(A/P)(K/Q)(G/T/E)(N/T/D)), or SEQ ID NO: 3 (PP(G/T/Q/V)(V/T/A)(R/H/T/S)(GN/NHP/SAA)).

Abstract: Described herein dog and cat food additives and compositions comprising secretory IgA.

Abstract: Disclosed are methods of altering metabolism of phosphate in a livestock via an antibody. The methods involve the development of an antibody against FGF-23 for the purpose of reducing phosphate excretion by an animal.

Abstract: Disclosed are methods of altering metabolism of phosphate in a livestock via an antibody. The methods involve the development of an antibody against FGF-23 for the purpose of reducing phosphate excretion by an animal.

Abstract: Described herein are methods of determining energy balance in individuals such as exercising individuals, individuals consuming a 13C-enriched test composition and individuals consuming a fixed diet with a known ?13C. The ?13C pre- and post-exercise, or pre- and post-consumption of the test beverage or fixed diet indicate whether the individual is in neutral or positive energy balance, or in energy deficit. The methods are particularly useful for individuals participating in weight management programs, and individuals under the care of health care professionals.

Abstract: Described herein are methods of use of purified preen oil, food and feed compositions containing purified preen oil, food and feed additives containing purified preen oil, and pharmaceutical compositions containing purified preen oil. Methods include treatment of chronic joint inflammation in humans and animals by orally administering purified preen oil. Also included are methods of feeding a growing fish by feeding the feeding the growing fish purified preen oil in amounts effective to improve survival and/or stimulate growth in the growing fish. Further included are methods of feeding live prey organisms purified preen oil, and feeding the live prey organisms to growing fish.

Abstract: A method of determining efficacy of an antimicrobial treatment in a subject includes calculating a breath delta value (BDV) for each of at least six breath samples acquired from the subject over a 24 hour period starting from when the subject has been administered the antimicrobial treatment, calculating a mean standard deviation of BDV (SD BDV) across the six or more breath samples; and determining that the antimicrobial treatment is effective when the SD BDV is less than or equal to 0.46, or determining that the antimicrobial treatment is ineffective when the SD BDV is greater than 0.46. Also included are methods of treating a subject in need of antimicrobial treatment.

Abstract: Described herein are interleukin-10 receptor-2 peptides, antibodies that bind the peptides, compositions including the peptides and antibodies and methods of use of the peptides and antibodies. The interleukin-10 receptor-2 peptide consists of an 8-15 amino acid sequence that includes SEQ ID NO: 1 ((I/V)P(P/K/V/E)P(E/K/R/Q)N(A/V)R), SEQ ID NO: 2 ((S/L/V)PAF(A/P)(K/Q)(G/T/E)(N/T/D)), or SEQ ID NO: 3 (PP(G/T/Q/V)(V/T/A)(R/H/T/S)(GN/NHP/SAA)).

Abstract: Described herein dog and cat food additives and compositions comprising secretory IgA.

Abstract: Described herein are methods of determining energy balance in individuals such as exercising individuals, individuals consuming a 13C-enriched test composition and individuals consuming a fixed diet with a known ?13C. The ?13C pre- and post-exercise, or pre- and post-consumption of the test beverage or fixed diet indicate whether the individual is in neutral or positive energy balance, or in energy deficit. The methods are particularly useful for individuals participating in weight management programs, and individuals under the care of health care professionals.

Abstract: Described herein are methods of preventing and/or treating inflammation in a barrier surface structure in an individual in need thereof by orally administering to the individual an anti-inflammatory amount of secretory IgA.

Abstract: Described herein are methods of use of purified preen oil, food and feed compositions containing purified preen oil, food and feed additives containing purified preen oil, and pharmaceutical compositions containing purified preen oil. Methods include treatment of chronic joint inflammation in humans and animals by orally administering purified preen oil. Also included are methods of feeding a growing fish by feeding the feeding the growing fish purified preen oil in amounts effective to improve survival and/or stimulate growth in the growing fish. Further included are methods of feeding live prey organisms purified preen oil, and feeding the live prey organisms to growing fish.

Abstract: Described herein are methods of use of purified preen oil, food and feed compositions containing purified preen oil, food and feed additives containing purified preen oil, and pharmaceutical compositions containing purified preen oil. Methods include treatment of chronic joint inflammation in humans and animals by orally administering purified preen oil. Also included are methods of feeding a growing fish by feeding the feeding the growing fish purified preen oil in amounts effective to improve survival and/or stimulate growth in the growing fish. Further included are methods of feeding live prey organisms purified preen oil, and feeding the live prey organisms to growing fish.

Abstract: A portable medical training manikin with a hollow torso body with a chest plate having slotted openings provided to enable realistic flexing of the chest plate along hinges engaged with a chest compression piston. The torso body has a realistic skin covering the torso and interconnected at a hinge. A chest compression piston supports and resists chest compressions performed by a user. The chest compression piston is engaged with the central chest plate of the torso body by a quick release mechanism having detent locks for securing the piston engaged with the chest plate. A two-piece tiltable head configuration enables detachment of the back half of the head piece, and inversion for nested stacking within the front half head piece. The hollow torso body is likewise configured for convenient stacking, including the compression pistons, in a carrying container.

Abstract: Disclosed are methods of altering metabolism of phosphate in a livestock via an antibody. The methods involve the development of an antibody against FGF-23 for the purpose of reducing phosphate excretion by an animal.

Abstract: Disclosed are methods of altering metabolism of phosphate in a livestock via an antibody. The methods involve the development of an antibody against FGF-23 for the purpose of reducing phosphate excretion by an animal.